Post by
venture009 on Nov 30, 2023 12:20pm
Immunogen Inc
The acquisition of Immunogen and it's ADC therapy is highligting this cancer therapy and the focus of large biotechs for future investments. Pfizer massive purchase of Seagen and now Abbvie's purchase of Immunogen. The question is BP now going to ignore virus's going forward and what doe this mean for ONC?
Comment by
venture009 on Nov 30, 2023 10:13pm
Noteable, like too many of ONC trials the patient population is too small for statisical significanse. If they had 40+ patients in their trial with the same results, I believe we would be getting more recognition. I also wonder if this may be causing some hesitancy in a BP coming forward with an offer.
Comment by
inthno on Nov 30, 2023 11:05pm
Trial size does make a different for sure and I have always wondered why they did not continue on to the next stage of the panc trial. It would have been done now and so much more information. Someone had to make the call and for a major reason and it has now been over a year so what would be the reason.
Comment by
Noteable on Dec 01, 2023 11:07am
" ... the technique of trying to misslead people is very subtle (very well known), but repetitive for one purpose" ..... would that purpose be to "trouble make" since such skeptics are usually not shareholders.
Comment by
Noteable on Dec 01, 2023 12:23pm
If you think that what you post is a reasonable question, then why dont you pose your questions to ONCY rather than here? We cant answer for ONCY, so what do you expect posting here? Ive already responded to your devils advocate purpose - where you posted mistruths disguised as questions.